Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China. KYBORA and ACA Pharma announced a strategic partnership that combines ACA Pharma’s innovative 30–90 day market-entry strategy via Macau with KYBORA’s deep network and dealmaking expertise across the global […]
Episode 7: CEO Insights: Immunotherapy Innovations, AI Challenges and Clinical Trial Observations In our new episode CEO Insights: Immunotherapy Innovations, AI Challenges and Clinical Trial Observations, our CEO & Founder, Alan Vanderborght, sits down with David Apelian, CEO at Theolytics. Together, they explore various current industry topics, focusing on exciting immunotherapy innovations, AI pros and cons and […]
KYBORA Capital is a life sciences focused investment bank that combines deep domain expertise with agile execution, offering a Managing Director a compelling platform to grow their franchise within a highly specialized sector. Position Summary We are seeking an experienced Managing Director to lead our FINRA-registered broker-dealer unit focused on the biopharmaceutical sector. As a […]
Shaping the Future of Life Sciences. KYBORA’s Founder and CEO, Alan Vanderborght, participated in BioArbor Life Science Forum in a special Fireside Chat in Ann Arbor, Michigan, an event where leading figures and innovators from the life sciences sector are brought together to discuss emerging challenges and opportunities. With more than 25 years guiding global […]
Episode 6: The AI Effect on the Biopharma Market In our latest episode, The AI Effect on the Biopharma Market, KYBORA‘s CEO Alan Vanderborght sits down for an insightful conversation with William Compton, SVP, Digital Enabling Functions and Colleague Services at Pfizer. Together, they explore the profound impact of AI across the industry, and what the […]
According to IQVIA Institute’s report “The Global Use of Medicines Outlook through 2029”, the global pharmaceutical landscape is entering a transformative phase. By 2029, global medicine spending is projected to reach $2.4 trillion, growing at a 5–8% CAGR. This growth is supported by sustained innovation, balanced by significant losses of exclusivity (LOE) due to patent […]
Episode 5: Global Biopharma Today: Funding Trends and Future Outlook In our latest episode, KYBORA‘s CEO, Alan Vanderborght, sits down with Richard Davies, Deputy Chairman of the Board at Alvotech, for a conversation about Richard’s extensive industry experience, the current state of Biopharma, funding hurdles and the future of the industry. Listen to the episode […]
KYBORA, a leading global advisory firm specializing in biopharma transactions, is proud to announce its role as exclusive advisor to Bioprofarma Bagó in a significant in-licensing agreement with Polaris. Under this strategic agreement, Bioprofarma Bagó (a fully owned subsidiary of Grupo Bagó), secured an exclusive licensing agreement with Polaris, to introduce ADI-PEG20 (ADZODI), a novel […]
KYBORA acted as the exclusive advisor to Xbrane Biopharma (Nasdaq Stockholm: XBRANE) on its strategic agreement with Alvotech for the divestment of its Cimzia® biosimilar candidate (XB003) and its R&D operations. The transaction, valued at approximately EUR 24 million, includes an upfront cash payment of approximately EUR 8.9 million, the assumption of approximately EUR 15.1 […]
Basel Area Business & Innovation Hosts Beyond Venture Capital Panel At this year’s BIO International Convention, the Basel Area Business & Innovation hosted a forward-looking panel titled “Beyond Venture Capital”, spotlighting how biotech companies can navigate today’s rapidly evolving funding landscape. In a conversation moderated by Kirsten Detrick, delegate of Business Location Switzerland, KYBORA’s CEO, […]
